Inhibrx, Inc. (INBX) Income Statement
INBX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsINBX revenue and net income
Where INBX's revenue goes
2025Each bar shows an amount and its share of revenue. INBX kept −10,773.5% of revenue as net income.
INBX profit margins
INBX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +550.0% | −16.0% | −36.7% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | −108.3% | — | — | — |
| EPS (diluted) | −107.7% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
INBX quarterly EPS vs estimates
Inhibrx beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 13, 2026 (estimate $-2.50).
INBX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $200,000 | $1.8M | $2.2M | $7.1M | $12.8M | $9.1M | $8.6M | $8.4M | $6.7M |
| Cost of revenue | $2.5M | $2.3M | $1.2M | $110.2M | $2.7M | $73.5M | $47.9M | $33.5M | $25.5M | $17.0M |
| Gross profit | −$1.2M | −$2.1M | $609,000 | −$108.0M | $4.4M | −$60.7M | −$38.8M | −$24.9M | −$17.1M | −$10.3M |
| Research & development | $113.0M | $203.7M | $190.6M | $110.2M | $71.4M | $73.5M | $47.9M | $33.5M | $25.5M | $17.0M |
| Sales, general & admin | $23.3M | $127.9M | $29.4M | $21.1M | $12.4M | $6.8M | $9.0M | $4.7M | $2.6M | $1.8M |
| Total operating expenses | $133.8M | $329.4M | $219.8M | $21.1M | $81.1M | $80.3M | $10.1M | $4.6M | $27.7M | $18.6M |
| Operating income | −$135.0M | −$331.4M | −$219.2M | −$129.1M | −$76.7M | −$67.4M | −$41.0M | −$29.5M | −$19.7M | −$12.1M |
| Interest income | $7.5M | $10.9M | $11.9M | — | — | — | — | — | — | — |
| Interest expense | $12.2M | $13.5M | $31.8M | $16.1M | $5.2M | $10.8M | $5.7M | $1.5M | $2.1M | — |
| Income before taxes | −$140.1M | $1.69B | −$239.7M | −$145.2M | −$81.8M | −$75.6M | −$50.5M | −$30.9M | −$21.8M | −$12.9M |
| Income taxes | $2,000 | $2,000 | $3,000 | $3,000 | $2,000 | $3,000 | $898,000 | $96,000 | $250,000 | −$4.6M |
| Net income | −$140.1M | $1.69B | −$241.4M | −$145.2M | −$81.8M | −$76.1M | −$51.4M | −$31.2M | −$19.4M | −$8.3M |
| EBITDA | −$125.4M | $1.70B | −$206.7M | −$125.8M | −$76.5M | −$66.4M | −$39.8M | −$28.8M | −$19.3M | −$11.9M |
| EPS (diluted) | −$9.04 | $118.11 | −$4.47 | −$3.36 | −$2.12 | −$2.02 | −$1.79 | −$1.12 | −$1.07 | — |
| Gross margin | −91.0% | −1,042.5% | 33.8% | −4,926.7% | 62.3% | −473.8% | −426.9% | −289.2% | −204.0% | −154.9% |
| Operating margin | −10,386.5% | −165,724.0% | −12,178.9% | −5,890.4% | −1,076.1% | −526.6% | −450.4% | −343.4% | −235.1% | −182.2% |
| Net margin | −10,773.5% | 843,786.0% | −13,408.9% | −6,625.3% | −1,147.6% | −594.3% | −565.3% | −362.6% | −231.7% | −124.0% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.3M | $0 | $100,000 | $0 | $100,000 | $0 | $1.6M | $119,000 |
| Cost of revenue | — | $537,000 | $564,000 | $582,000 | $662,000 | $675,000 | $689,000 | $760,000 | $475,000 | $360,000 | $298,000 | $304,000 |
| Gross profit | — | −$537,000 | −$564,000 | −$582,000 | $638,000 | −$675,000 | −$589,000 | −$760,000 | $100,000 | −$360,000 | $1.3M | −$185,000 |
| Research & development | $23.9M | $24.7M | $25.3M | $28.5M | $22.3M | $36.9M | $33.4M | $38.2M | $67.6M | $63.6M | $81.8M | $38.1M |
| Sales, general & admin | $8.2M | $5.7M | $5.6M | $5.3M | $6.4M | $6.0M | $16.7M | $8.0M | $93.4M | $10.1M | $7.9M | $7.9M |
| Total operating expenses | $32.1M | $30.4M | $30.4M | $33.2M | $28.0M | $42.2M | $49.3M | $46.0M | $161.0M | $73.5M | $89.6M | $45.6M |
| Operating income | −$32.1M | −$30.9M | −$30.9M | −$33.8M | −$27.4M | −$42.9M | −$49.9M | −$46.8M | −$160.9M | −$73.8M | −$88.3M | −$45.8M |
| Interest income | $1.3M | $1.0M | $1.3M | $1.8M | $2.1M | $2.3M | $2.0M | $2.9M | $2.7M | $3.3M | — | — |
| Interest expense | $5.7M | $3.5M | $3.2M | $3.2M | $3.1M | $2.7M | $0 | $0 | $5.4M | $8.1M | $8.2M | $8.1M |
| Income before taxes | −$36.6M | −$33.4M | −$32.8M | −$35.3M | −$28.7M | −$43.3M | −$47.9M | −$43.9M | $1.86B | −$78.7M | −$93.6M | −$51.8M |
| Income taxes | $3,000 | — | — | — | $2,000 | — | — | — | $2,000 | $316,724 | −$4,000 | $2,000 |
| Net income | −$36.6M | −$33.4M | −$32.8M | −$35.3M | −$28.7M | −$43.3M | −$47.9M | −$43.9M | $1.86B | −$78.7M | −$93.6M | −$51.8M |
| EBITDA | −$30.5M | −$29.4M | −$29.1M | −$31.5M | −$24.9M | −$39.9M | −$47.2M | −$43.1M | $1.86B | −$70.2M | −$88.0M | −$43.3M |
| EPS (diluted) | −$2.34 | −$2.15 | −$2.11 | −$2.28 | −$1.85 | −$2.80 | −$3.09 | −$2.84 | $125.48 | −$1.44 | — | — |
| Gross margin | — | — | — | — | 49.1% | — | −589.0% | — | 100.0% | — | 81.8% | −155.5% |
| Operating margin | — | — | — | — | −2,106.8% | — | −49,928.0% | — | −160,898.0% | — | −5,403.2% | −38,510.1% |
| Net margin | — | — | — | — | −2,204.2% | — | −47,865.0% | — | 1,858,011.0% | — | −5,728.5% | −43,520.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in INBX's financial statements (latest annual report filed March 19, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
INBX financial results
In fiscal year 2025 (ended December 31, 2025), Inhibrx reported revenue of $1.3 million, up 550.0% from the year before. It had a net loss of $140.1 million, a net profit margin of −10,773.5%. Diluted earnings per share came to −$9.04. Over five years revenue grew at an average rate of −36.7% a year.
See the INBX stock overview for the latest quote and news, or the INBX chart for price history and technical indicators.
INBX income statement FAQ
What is Inhibrx's annual revenue?
Inhibrx reported total revenue of $1.3 million for fiscal year 2025, which ended on December 31, 2025. That was up 550.0% from $0.2 million the previous year.
Is Inhibrx profitable?
No. Inhibrx reported a net loss of $140.1 million in fiscal 2025, a net profit margin of −10,773.5%; its operating margin was −10,386.5%.
What is Inhibrx's gross margin?
Inhibrx's gross margin was −91.0% in fiscal 2025: for every $100 of revenue, Inhibrx kept $-91 after the direct cost of its products and services.
How much does Inhibrx spend on research and development?
Inhibrx spent $113.0 million on research and development in fiscal 2025, 8,694.5% of revenue.
How fast is Inhibrx growing?
Revenue grew −36.7% a year on average over the last five fiscal years, from $12.8 million to $1.3 million.
What are Inhibrx's earnings per share?
Inhibrx earned $-9.04 per diluted share in fiscal 2025, compared with $118.11 a year earlier.
When will Inhibrx report its next earnings?
Inhibrx is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 after the market closes.
When does Inhibrx's fiscal year end?
Inhibrx's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 19, 2026.